BioSpace News Archive

From collaboration to licensing options in less than 18 months

CytoReason will receive from Pfizer payments potentially equaling up to low double digit millions of US$ for technology access fees, research support and certain success-based payments.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Dr. Mark Pykett to Chief Scientific Officer and Dr. Neil Almstead to Chief Technical Operations Officer.

Civica Rx has announced that 12 health systems, representing approximately 250 hospitals across the United States, have joined the new not-for-profit generic drug company as founding members.

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today pre-announced its unaudited fourth quarter 2018 global net product revenues for ONPATTRO and provided additional updates on the product’s commercial launch.

Endologix, Inc. (the “Company”) (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the fourth quarter ended December 31, 2018 is expected to be approximately $34 million.

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited revenues for the fourth quarter and full year ended December 31, 2018.

Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided 2018 highlights, 2019 guidance and commercialization plans for INBRIJA at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco.

Wellness incentives and fitness amenities are most commonly sought by employees and provided by companies

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today highlighted progress in its pain management and chemotherapy-induced nausea and vomiting (CINV) franchises.